Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival.
Bristol Myers Squibb announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator?s choice of chemotherapy as a first-line treatment for patients.
First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free survival with Opdivo plus Yervoy compared to.
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy
Combination of.